Stem cell-based therapies, promises, obstacles, discordance, and the agora

Perspectives in Biology and Medicine

Volumn 55, Issue 1, 2012, Pages 1-25

  Eggleson, Kathleen K ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857831167     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: 10.1353/pbm.2012.0001     Document Type: Article

References (134)

1. Adeyi, O., O. Smith, and S. Robles. 2007. Public policy and the challenge of chronic noncommunicable diseases.Washington,DC: International Bank for Reconstruction and Development/World Bank.
2. Almad, A., F. R. Sahinkaya, and D.M. McTigue. 2011. Oligodendrocyte fate after spinal cord injury. Neurotherapeutics 8(2):262-73.
3. Alsaleh, F.M., F. J. Smith, and K.M. Taylor. 2011. Experiences of children/young people and their parents, using insulin pump therapy for the management of type 1 diabetes: Qualitative review. J Clin PharmTher. doi:10.1111/j.1365-2710.2011.01283.x.
4. Amariglio, N., et al. 2009. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Medicine 6(2): e1000029.
5. Arboleda, D., et al. 2011. Transplantation of predifferentiated adipose-derived stromal cells for the treatment of spinal cord injury. Cell Mol Neurobiol 31(7):1113-22.
6. Aviv, V., et al. 2009. Exendin-4 promotes liver cell proliferation and enhances the PDX-1-induced liver to pancreas transdifferentiation process. J Biol Chem 284(48): 33509-20.
7. Azzi, J., et al. 2010. Immunological aspects of pancreatic islet cell transplantation. Expert Rev Clin Immunol 6(1):111-24.
8. Balsam, L. B., et al. 2004. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 428(6983):668-73.
9. Bergmann, O., et al. 2009. Evidence for cardiomyocyte renewal in humans. Science 324 (5923):98-102.
10. Berman, D.M., et al. 2010.Mesenchymal stem cells enhance allogeneic islet engraftment in nonhuman primates. Diabetes 59(10):2558-68.
11. Blakemore, C. 2007. From the "public understanding of science" to scientists' understanding of the public:The Dana Foundation series on neuroethics.Washington, DC: Dana Press.
12. Braunwald, E. 1997. Shattuck lecture. Cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities. N Engl J Med 337(19):1360-69.
13. British-North American Committee (BNAC). 2004. A guide to the benefits, responsibilities, and opportunities of embryonic stem cell research.Vol. BN-47. http://www.acus.org/docs/0406-Guide_Benefits_Responsibilities_Opportunities_Embryonic_Stem_Cell_Research.pdf.
14. Bromberg, J. S., et al. 2007.The islet transplant experiment:Time for a reassessment. Am J Transplant 7(10):2217-18.
15. Bryson, C. 2004. The fluoride deception. NewYork: Seven Stories Press.
16. Burt, R. K., et al. 2002. Hematopoietic stem cell therapy for type 1 diabetes: Induction of tolerance and islet cell neogenesis. Autoimmun Rev 1(3):133-38.
17. Campbell, P. M., et al. 2007. High risk of sensitization after failed islet transplantation. Am J Transplant 7(10):2311-17.
18. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). 2010. National health and nutrition examination survey data. Hyattsville, MD: U.S. Dept. of Health and Human Services.
19. Chandra, V., et al. 2009. Generation of pancreatic hormone-expressing islet-like cell aggregates from murine adipose tissue-derived stem cells. Stem Cells 27(8):1941-53.
20. Chong, A. S., et al. 2006.Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration. Science 311(5768):1774-75.
21. Christoforou, N., et al. 2010. Implantation of mouse embryonic stem cell-derived cardiac progenitor cells preserves function of infarcted murine hearts. PLoS One 5(7): e11536.
22. Cooper, C. B. 2011.Media literacy as a key strategy toward improving public acceptance of climate change science. Bioscience 61(3):231-37.
23. Couri, C. E., et al. 2009.C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 301(15):1573-79.
24. Couzin-Frankel, J. 2010. Immunology: Replacing an immune system gone haywire. Science 327(5967):772-74.
25. Crowe, M. J., et al. 1997.Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med 3(1):73-76.
26. Dean, S. K., et al. 2006. Differentiation of encapsulated embryonic stem cells after transplantation. Transplantation 82(9):1175-84.
27. Diabetes Control and Complications Trial Research Group. 1998. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial: A randomized, controlled trial. Ann Intern Med 128(7): 517-23.
28. Dieguez-Acuna, F., et al. 2010. Proteomics identifies multipotent and low oncogenic risk stem cells of the spleen. Int J Biochem Cell Biol 42(10):1651-60.
29. Dimomeletis, I., et al. 2010.Assessment of human MAPCs for stem cell transplantation and cardiac regeneration after myocardial infarction in SCID mice. Exp Hematol 38(11):1105-14.
30. Dobzhansky, T. 1964. Biology, molecular and organismic. Am Zoologist 4:443-52.
31. Doull, J. et al. 2006. Fluoride in drinking water:A scientific review of EPA's standards. Washington, DC: National Academies Press.
32. Dressel, R., et al. 2010. Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells. FASEB J 24(7):2164-77.
33. Eaton, S. B., L. Cordain, and S. Lindeberg. 2002. Evolutionary health promotion:A consideration of common counterarguments. Prevent Med 34(2):119-23.
34. Eaton, S. B., et al. 2002. Evolutionary health promotion. Prevent Med 34(2):109-18.
35. Faustman, D. L., and M. Davis. 2010. Stem cells in the spleen:Therapeutic potential for sjogren's syndrome, type I diabetes, and other disorders. Int J Biochem Cell Biol 42(10): 1576-79.
36. Fawcett, J.W., et al. 2007. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: Spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 45(3):190-205.
37. Fiorina, P., et al. 2009. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 183(2): 993-1004.
38. Fitch, M.T., and J. Silver. 2008. CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure. Exp Neurol 209(2):294-301.
39. Geron. 2011. http://www.geron.com/GRNOPC1Trial/. [Note: Geron halted the trial on Nov. 14, 2011.]
40. Gibbons, M. 1999. Science's new social contract with society. Nature 402(6761 suppl.): C81-C84.
41. Greenwood, H. L., et al. 2006. Regenerative medicine and the developing world. PLoS Med 3(9):e381.
42. Guest, J. D., E. D. Hiester, and R. P. Bunge. 2005. Demyelination and schwann cell responses adjacent to injury epicenter cavities following chronic human spinal cord injury. Exp Neurol 192(2):384-93.
43. Hess, D., et al. 2003. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotechnol 21(7):763-70.
44. Hill, C. E., M. S. Beattie, and J. C. Bresnahan. 2001.Degeneration and sprouting of identified descending supraspinal axons after contusive spinal cord injury in the rat. Exp Neurol 171(1):153-69.
45. Hirschhorn, J.N. 2003.Genetic epidemiology of type 1 diabetes. Pediatr Diabetes 4(2):87-100.
46. Hofstetter, C. P., et al. 2005.Allodynia limits the usefulness of intraspinal neural stem cell grafts: Directed differentiation improves outcome. Nat Neurosci 8(3):346-53.
47. International Society for Stem Cell Research (ISSCR). 2008. Patient handbook on stem cell therapies. http://www.isscr.org/clinical_trans/pdfs/ISSCRPatientHandbook.pdf.
48. Jurewicz, M., et al. 2010. Congenic mesenchymal stem cell therapy reverses hyperglycemia in experimental type 1 diabetes. Diabetes 59(12):3139-47.
49. Kakulas, B.A. 1999.A review of the neuropathology of human spinal cord injury with emphasis on special features. J Spinal Cord Med 22(2):119-24.
50. Kang, H. M., et al. 2009. Insulin-secreting cells from human eyelid-derived stem cells alleviate type I diabetes in immunocompetent mice. Stem Cells 27(8):1999-2008.
51. Keirstead, H. S., and W. F. Blakemore. 1997. Identification of post-mitotic oligodendrocytes incapable of remyelination within the demyelinated adult spinal cord. J Neuropathol Exp Neurol 56(11):1191-201.
52. Kennedy, D. 2006. Editorial retraction. Science 311(5759):335.
53. Kilkenny, C., et al. 2009. Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One 4(11): e7824.
54. Kim, K., et al. 2010. Epigenetic memory in induced pluripotent stem cells. Nature 467 (7313):285-90.
55. King, M., et al. 2008.Humanized mice for the study of type 1 diabetes and beta cell function. Ann NY Acad Sci 1150:46-53.
56. Kiuru, M., et al. 2009.Genetic control of wayward pluripotent stem cells and their progeny after transplantation. Cell Stem Cell 4(4):289-300.
57. Knowles, P. 2009.Obesity is a lifelong health problem. PsycCRITIQUES 54(26). http://search.proquest.com/docview/621870697?accountid=12874.
58. Kodama, S., et al. 2003. Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 302(5648):1223-27.
59. Konner, M. 2001. Evolution and our environment:Will we adapt? West J Med 174(5): 360-61.
60. Krishna, K.A., G.V. Rao, and K. S. Rao. 2007. Stem cell-based therapy for the treatment of type 1 diabetes mellitus. Regen Med 2(2):171-77.
61. Kroon, E., et al. 2008. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 26(4):443-52.
62. Kwon, B. K., L.H. Sekhon, and M.G. Fehlings. 2010. Emerging repair, regeneration, and translational research advances for spinal cord injury. Spine 35(21 suppl.):S263-S270.
63. Laflamme, M.A., and C. E. Murry. 2011. Heart regeneration. Nature 473(7347):326-35.
64. Lechner, A., et al. 2004. No evidence for significant transdifferentiation of bone marrow into pancreatic beta-cells in vivo. Diabetes 53(3):616-23.
65. Lee, R.H., et al. 2006.Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Nat Acad Sci USA 103(46):17438-43.
66. Lee, Y. K., et al. 2011.Current perspective of stem cell therapies for cardiac regeneration. Therapy 8(1):69.
67. Li, H.Y., et al. 2010. Induction of insulin-producing cells derived from endometrial mesenchymal stem-like cells. J Pharmacol Exp Ther 335(3):817-29.
68. Lonyai, A., et al. 2008.The promise of Hox11 stem cells of the spleen for treating autoimmune diseases. Horm Metab Res 40(2):137-46.
69. Madec, A.M., et al. 2009.Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 52(7):1391-99.
70. Madonna, R., and R. De Caterina. 2011. Stem cells and growth factor delivery systems for cardiovascular disease. J Biotechnol 154(4):291-97.
71. Maehr, R. 2011. iPS cells in type 1 diabetes research and treatment. Clin Pharmacol Ther 89(5):750-53.
72. Manohar, R., and E. Lagasse. 2009.Transdetermination: A new trend in cellular reprogramming. Mol Ther 17(6):936-38.
73. Marban, E. 2007. Big cells, little cells, stem cells:Agents of cardiac plasticity. Circ Res 100 (4):445-46.
74. Mathews, S. C., et al. 2010. A national study examining emergency medicine specialty training and quality measures in the emergency department. Am J Med Qual 25(6): 429-35.
75. Mathiasen, A.B., M. Haack-Sorensen, and J. Kastrup. 2009.Mesenchymal stromal cells for cardiovascular repair:Current status and future challenges. Future Cardiol 5(6):605-17.
76. Milanetti, F., et al. 2010. Autologous hematopoietic stem cell transplantation for childhood autoimmune disease. Pediatr Clin North Am 57(1):239-71.
77. Miura, K., et al. 2009.Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 27(8):743-45.
78. Mooney, C. 2011.The science of why we don't believe science: How our brains fool us on climate, creationism, and the vaccine-autism link. Mother Jones (May/June). http://motherjones.com/politics/2011/03/denial-science-chris-mooney?page=1.
79. Moretto-Zita, M., et al. 2010. Phosphorylation stabilizes nanog by promoting its interaction with Pin1. Proc Nat Acad Sci USA 107(30):13312-17.
80. Mozid, A.M., et al. 2011. Stem cell therapy for heart diseases. Br Med Bull 98:143-59.
81. Muller-Ehmsen, J., et al 2006. Effective engraftment but poor mid-term persistence of mononuclear and mesenchymal bone marrow cells in acute and chronic rat myocardial infarction. J Mol Cell Cardiol 41(5):876-84.
82. Murry, C. E., et al. 2004.Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature 428(6983):664-68.
83. Nadal-Ginard, B., et al. 2003.Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res 92(2):139-50.
84. Nagaya, M., et al. 2009.Adult mouse intrahepatic biliary epithelial cells induced in vitro to become insulin-producing cells. J Endocrinol 201(1):37-47.
85. National Center for Health Statistics (NCHS). 2011.Health,United States, 2010:With special feature on death and dying. Hyattsville,MD: NCHS.
86. National Institutes of Health (NIH). 2011a. Report grants:Applications, awards, success rates, and total funding, by IC,mechanism, activity code, and funding source for 2010. http://report.nih.gov/frrs/index.aspx.
87. National Institutes of Health (NIH). 2011b. NIH RePORT (research portfolio online reporting tool). http://report.nih.gov/rcdc/categories/.
88. National Prevention Council. 2011. National prevention strategy. Washington, DC: U.S. Dept. of Health and Human Services, Office of the Surgeon General.
89. Naujok, O., et al. 2009. Changes in gene expression and morphology of mouse embryonic stem cells on differentiation into insulin-producing cells in vitro and in vivo. Diabetes Metab Res Rev 25(5):464-76.
90. Neshati, Z., et al. 2010. Differentiation of mesenchymal stem cells to insulin-producing cells and their impact on type 1 diabetic rats. J Physiol Biochem 66(2):181-87.
91. Nesse, R.M., and G. C. Williams. 1998. Evolution and the origins of disease. Sci Am 279 (5):86-93.
92. Ngoc, P. K., et al. 2011. Improving the efficacy of type 1 diabetes therapy by transplantation of immunoisolated insulin-producing cells. Hum Cell 24(2):86-95.
93. Nishio, J., et al. 2006. Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution. Science 311(5768):1775-78.
94. Nygren, J. M., et al. 2004. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med 10(5):494-501.
95. Pinzon, A., et al. 2008. A re-assessment of erythropoietin as a neuroprotective agent following rat spinal cord compression or contusion injury. Exp Neurol 213(1):129-36.
96. Pittenger, M. F., and B. J. Martin. 2004.Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 95(1):9-20.
97. Regaldo, A. 2011. Stem-cell gamble. Technol Rev (July/Aug.). http://www.technologyreview.com/biomedicine/37787/?nlid=4625.
98. Roger, V. L., et al. 2011. Heart disease and stroke statistics. 2011 update: A report from the American Heart Association. Circulation 123(4):e18-e209.
99. Rosengren, A. H., et al. 2009. Bone marrow transplantation stimulates pancreatic betacell replication after tissue damage. Islets 1(1):10-18.
100. Ross, L. F., and L. H. Philipson. 2007. Ethics of hematopoietic stem cell transplantation in type 1 diabetes mellitus. JAMA 298(3):285; author reply, 285-86.
101. Rowland, J.W., et al. 2008. Current status of acute spinal cord injury pathophysiology and emerging therapies: Promise on the horizon. Neurosurg Focus 25(5):E2.
102. Saketkhou, B. B., et al. 1997. Emergency department use of aspirin in patients with possible acute myocardial infarction. Ann Intern Med 127(2):126-29.
103. Schafer, M. 2009. From public understanding to public engagement: An empirical assessment of changes in science coverage. Sci Commun 30(4):475-505.
104. Schuldiner, M., J. Itskovitz-Eldor, and N. Benvenisty. 2003. Selective ablation of human embryonic stem cells expressing a "suicide" gene. Stem Cells 21(3):257-65.
105. Segers, V. F., and R.T. Lee. 2008. Stem-cell therapy for cardiac disease. Nature 451(7181): 937-42.
106. Shao, S., et al. 2011.Correction of hyperglycemia in type 1 diabetic models by transplantation of encapsulated insulin-producing cells derived from mouse embryo progenitor. J Endocrinol 208(3):245-55.
107. Shapiro, A. M., et al. 2006. International trial of the edmonton protocol for islet transplantation. N Engl J Med 355(13):1318-30.
108. Sharp, K.G., et al. 2010.A re-assessment of a combinatorial treatment involving schwann cell transplants and elevation of cyclic AMP on recovery of motor function following thoracic spinal cord injury in rats. Exp Neurol (Dec 30). doi: 10.1016/j.expneurol. 2010.12.020.
109. Silver, J., and J.H. Miller. 2004.Regeneration beyond the glial scar. Nat Rev Neurosci 5(2): 146-56.
110. Snarski, E., et al. 2011. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. Bone Marrow Transplant 46(4):562-66.
111. Sordi, V., et al. 2010. Mesenchymal cells appearing in pancreatic tissue culture are bone marrow-derived stem cells with the capacity to improve transplanted islet function. Stem Cells 28(1):140-51.
112. Stauffer, K. A. 2010. Anatomy and physiology for psychotherapists: Connecting body and soul. NewYork: Norton.
113. Steward, O., et al. 2006.A re-assessment of the consequences of delayed transplantation of olfactory lamina propria following complete spinal cord transection in rats. Exp Neurol 198(2):483-99.
114. Steward, O., et al. 2008.A re-assessment of the effects of a nogo-66 receptor antagonist on regenerative growth of axons and locomotor recovery after spinal cord injury in mice. Exp Neurol 209(2):446-68.
115. Taneera, J., et al. 2006. Failure of transplanted bone marrow cells to adopt a pancreatic beta-cell fate. Diabetes 55(2):290-96.
116. Thomas, K. E., and L. D. Moon. 2011.Will stem cell therapies be safe and effective for treating spinal cord injuries? Br Med Bull 98:127-42.
117. Thonhoff, J. R., L. Ojeda, and P. Wu. 2009. Stem cell-derived motor neurons: Applications and challenges in amyotrophic lateral sclerosis. Curr Stem Cell ResTher 4(3):178-99.
118. Thuret, S., L. D. Moon, and F. H. Gage. 2006.Therapeutic interventions after spinal cord injury. Nat Rev Neurosci 7(8):628-43.
119. Tsuji, O., et al. 2010. Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. Proc Nat Acad Sci USA 107(28):12704-9.
120. Tzukerman, M., et al. 2003. An experimental platform for studying growth and invasiveness of tumor cells within teratomas derived from human embryonic stem cells. Proc Nat Acad Sci USA 100(23):13507-12.
121. Urbanek, K., et al. 2005. Cardiac stem cells possess growth factor-receptor systems that after activation regenerate the infarcted myocardium, improving ventricular function and long-term survival. Circ Res 97(7):663-73.
122. van der Bogt, K. E., et al. 2008. Comparison of different adult stem cell types for treatment of myocardial ischemia. Circulation 118(14 suppl.):S121-S129.
123. Vardanyan, M., et al. 2010. Pancreas vs. islet transplantation: A call on the future. Curr Opin Organ Transplant 15(1):124-30.
124. Voltarelli, J. C., et al. 2007.Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 297(14):1568-76.
125. Voltarelli, J. C., et al. 2008.Autologous hematopoietic stem cell transplantation for type 1 diabetes. Ann NY Acad Sci 1150:220-29.
126. Wagner, R.T., et al. 2010. Stem cell approaches for the treatment of type 1 diabetes mellitus. Transl Res 156(3):169-79.
127. Wainwright, S. P., et al. 2006. From bench to bedside? biomedical scientists' expectations of stem cell science as a future therapy for diabetes. Soc Sci Med 63(8):2052-64.
128. Wen, Y., B. Chen, and S.T. Ildstad. 2011. Stem cell-based strategies for the treatment of type 1 diabetes mellitus. Exp Opin Biol Ther 11(1):41-53.
129. Yanovski, S. Z., and J. A. Yanovski. 2011. Obesity prevalence in the United States: Up, down, or sideways? N Engl J Med 364(11):987-89.
130. Yechoor, V., et al. 2009a.Gene therapy with neurogenin 3 and betacellulin reverses major metabolic problems in insulin-deficient diabetic mice. Endocrinology 150(11):4863-73.
131. Yechoor, V., et al. 2009b.Neurogenin3 is sufficient for transdetermination of hepatic progenitor cells into neo-islets in vivo but not transdifferentiation of hepatocytes. Dev Cell 16(3):358-73.
132. Yeghiazarians, Y., et al. 2009. Injection of bone marrow cell extract into infarcted hearts results in functional improvement comparable to intact cell therapy. Mol Ther 17(7): 1250-56.
133. Zalzman, M., L. Anker-Kitai, and S. Efrat. 2005. Differentiation of human liver-derived, insulin-producing cells toward the beta-cell phenotype. Diabetes 54(9):2568-75.
134. Zhong, B., et al. 2011. Safeguarding nonhuman primate iPS cells with suicide genes. Mol Ther 19(9):1667-75.